 November, HealthSTATS successfully conducted its first training session for the Principle Investigator located at Prauge, Czech Republic for the upcoming medical trial for a pharmachetical company.
|
|
| November, A-PULSE CASP® granted 510(k) clearance by U.S. the Food and Drug Administration (FDA). |
|
| November, Appointment of UMAX MEDICAL as distributor for South Korea and CARDIOGRADE LLC as distributor for U.S.A. |
|
| November, New Four BPro centre at SATA (SATA Jurong Medical Centre, SATA Uttamram Medical Centre, SATA Woodlands Medical Centre and SATA Chinatown Medical Centre). |
|
| October, Appointment of MEDITECH as distributor for Sweden, Norway, Denmark and Finland |
|
| October, HealthSTATS obtained CE MDD Mark for A-PULSE CASP™ Application Software |
|
| September, HealthSTATS obtained KFDA (S.Korea) product approval for BPro |
|
| September, HealthSTATS obtained PMDA (Japan) accreditation approval |
|
| September, HealthSTATS obtained class II license for BPro with Health Canada |
|
 July, New BPro centre at Singapore Heart Foundation (Bishan)
|
|
|
May, HealthSTATS successfully conduct invasive clinical trial for CASP in Gleneagles hospital; Prof Bryan Williams (UK, Leicester) and Dr Peter Yan (Singapore, Gleneagles Hospital) are principal investigators.
|
|
|
|
|
